Shows / Vital Health Podcast
Vital Health Podcast
Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast. Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and…
Episodes
Vital Health PodcastChristian Schneider, CMO Biopharma Excellence
Christian Schneider is the Chief Medical Officer of Biopharma Excellence, and was formerly the Chief Scientific Officer at the UK’s MHRA. He was the Medical…
Vital Health PodcastBettina Ryll at the 2023 ESMO Conference
On this Vital Health Podcast, Duane Schulthess has a conversation with Bettina Ryll, the founder of the Melanoma Patient Network Europe. Bettina is regarded as…
Vital Health PodcastDan Leonard, Executive Director, We Work For Health
Dan is the newly appointed Executive Director of We Work For Health, bringing more than two decades of experience in advocacy, policy, and public affairs to…
Vital Health PodcastCancer Drug Developer Dr. Steve Potts' Congressional Testimony on the IRA
In this Vital Health Podcast, we’re speaking with Steve Potts before his congressional testimony for the U.S. House Committee on Energy and Commerce. Steve…
Vital Health PodcastAmy Miller and the PhRMA Foundation Push the R&D Envelope
In this vital health podcast, we’re speaking with Amy M. Miller, the recently appointed President of the PhRMA Foundation. Amy has held nonprofit leadership…
Vital Health PodcastVT’s Grumpy Old Men on Price Controls and IP Attacks
The U.S. Congress and Biden Administration’s attacks on IP and Drug Pricing continue unabated as the 2024 election approaches. In this Vital Health Podcast…
Vital Health PodcastTaking the Helm Mid Drug Pricing Maelstrom
In this Vital Health Podcast, Duane Schulthess speaks with Rachel King, the Interim CEO of the Biotechnology Innovation Organization (BIO), who is steering the…
Vital Health PodcastBest-of Edition: Looking back on the COVID-19 outbreak part 2
In this Best-Of edition of the Vital Health Podcast, we’re looking back on the outbreak of the COVID-19 pandemic and discussions we had with statistician…
Vital Health PodcastBest-of Edition: Looking back on the COVID-19 outbreak
In this Best-Of edition of the Vital Health Podcast, we're looking back on the outbreak of the COVID-19 pandemic, and conversations with Epidemiologist Martin…
Vital Health PodcastCMS' Restrictions on Alzheimer's Drugs
In this Vital Health Podcast, Duane Schulthess speaks with John Dwyer. John is a serial entrepreneur, having successfully built and sold two healthcare…
Vital Health PodcastBiocom California Grapples with Regulatory Assaults on all Fronts
With the Inflation Reduction Act now law, there are mounting concerns that its drug pricing revisions will have a huge negative impact on the California…
Vital Health PodcastAmitabh Chandra - IRA’s potential impact on the US biopharma ecosystem
Amitabh Chandra is the director of health policy research at the Harvard Kennedy School of Government, and a professor of business administration at Harvard…
Vital Health PodcastNJ’s Biopharma Sector in a Price Controlled World
In this Vital Health Podcast, we speak with Debbie Hart, President & CEO of BioNJ about the direct impacts of the Inflation Reduction Act upon her members…
Vital Health PodcastIRA’s Impact on Orphan Therapies – David Meeker
A Boston Success story, Rhythm Pharmaceuticals brought to market an innovative orphan therapy treating an extremely rare genetic disorder which causes…
Vital Health PodcastNick Shipley - IRA’s Impact on the Biopharma Ecosystem
This Vital Health Podcast was recorded at the BIO international Conference on the afternoon of the release of Vital Transformation’s research study outlining…
Vital Health PodcastNikolai Brun - Improving Europe's Biopharma Legislation
Nikolai Brun is a rare regulator who has rolled up his sleeves and successfully helped bring a therapy to market. He was part of a team at Genmab that…
Vital Health PodcastEU Cost Effectiveness Models Threaten Vulnerable U.S. Patients
The Quality Adjusted Life Year, or QALY, was invented at the UK’s University of York by Prof Alan Williams in the 1970s. Some currently engaged in the bitter…
Vital Health PodcastAndrew Roddam, CEO of Our Future Health
Andrew Roddam is the CEO of Our Future Health, the UK’s largest ever health research programme. The objective of Our Future Health is to bring together up to…
Vital Health PodcastAttacks on Bayh-Dole Put University Research at Risk
For the last several years in DC, a debate has raged as to the appropriate roles of industry, academia, and the NIH for R&D in the biopharma sector. With the…
Vital Health PodcastCalifornia Life Sciences’ Response to the Inflation Reduction Act
Known for sunshine, Hollywood Movies, Mikey Mouse, and Silicon Valley, California has been at the center of global biotech for nearly half a century. The 1976…
Vital Health Podcast"Bayh–Dole Cannot be Used for Controlling Prices"
On this Vital Health Podcast, we speak to Joseph Allen, the Executive Director of the Bayh-Dole Coalition. Joe served as a Senior Staff Member of former…
Vital Health PodcastPrice Controls put US Biopharma at Risk
Vital Transformation’s Grumpy Old Men discuss their recently published research which found that 60% of FDA approved medicines from 2011- 2020 originated in…
Vital Health PodcastPatrick Kilbride - The Dangers of March-In Rights
On October 7th, Health and Human Services Secretary Xavier Becerra said that the use of March-In Rights to control the pricing of medicines was not, “Off the…
Vital Health PodcastJohn LaMattina, Defending Pharma & Profits
John LaMattina is the author of several highly respected books showcasing a deep insider's perspective of the biopharma industry. His latest book, "Pharma and…
Vital Health PodcastSmall Molecules Get Short Shrift, Jeff Jonker and the IRA
With the passage of the Inflation Reduction Act (IRA), the US Government has fully embraced the idea of mandating price controls for therapies paid for by…
Vital Health PodcastThe Accelerated Approval Pathway is Vital for Rare Diseases
Proposed federal and state policies to restrict coverage and access to biomedical innovations approved through the FDA’s accelerated approval pathway are…
Vital Health PodcastIRA's Impact on Biopharma Innovation with Amitabh Chandra
With the US Inflation Reduction Act now law, many in Washington DC are saying that it’s provisions reducing pricing by $80 billion dollars annually in Medicare…
Vital Health PodcastNovaQuest’s Devin Rosenthal on BioPharma Investing in a Post IRA World
On this Vital Health Podcast, Duane Schulthess speaks with Devin Rosenthal, Vice President at NovaQuest Capital Management, who is responsible for the firm’s…
Vital Health PodcastHans Sauer is Sour on the WTO’s Waivers of mRNA IP
On June 17th, a Rubicon of sorts was crossed in Geneva as The World Trade Organization (WTO) agreed to the compulsory licensing for COVID-19 vaccines. In plain…
Vital Health PodcastNIH’s Impact on FDA Approvals is Statistically Zero, with Vital Transformation's Grumpy Old Men
Our podcast features Vital Transformation’s Grumpy Old Men (Harry Bowen, Joseph Hammang, and Duane Schulthess) and their recently published peer review study…
Vital Health PodcastPaul Neureiter on European Innovation, US Legislation, and China’s Biopharmaceutical Growth
The covid pandemic has brought into sharp focus the benefits as well as the challenges posed by the global supply chain related to the development of…
Vital Health PodcastCEOi’s John Dwyer on accelerated approvals, CMS, and Alzheimer’s Disease
What do you do when you’ve been an entrepreneur, and have successfully built and sold two healthcare start-ups to 3M and Aetna? If you’re John Dwyer, you…
Vital Health PodcastSSR Health’s Richard Evans on Medicare Price Controls
With the passage of the Inflation Reduction Act by the US Senate, the US is now on the cusp of implementing very aggressive drug pricing controls within…
Vital Health PodcastMichele Oshman – Driving Innovation for the US’ Biotech State Associations
Michele Oshman is Vice President of External Affairs of BIO, and the Executive Director of BIO’s Council of State Bioscience Associations (CSBA), advancing…
Vital Health PodcastJohn M. O'Brien’s Hot Takes on March-in, Co-Pays, PBMs, CMS, and Patient Access
John Michael O'Brien was recently appointed as the president and Chief Executive Officer of the National Pharmaceutical Council (NPC), one of the key…
Vital Health PodcastRutgers’ Gary Branning Untangles a PBM Web of Complexity
On May 5th of this year, a very strange thing happened. For the first time in memory, the Pharmaceutical Benefit Managers, or PBMs, who act as the go-between…
Vital Health PodcastJoe Panetta Steers Biocom California’s Members Through Increasingly Stormy Seas
It seems every week we hear of another new proposal out of Washington DC to ‘fix’ drug pricing, and many of the companies that would be impacted by these…
Vital Health PodcastAccelerated Approval Study Release - A Vital Pathway for Patients
Recorded live at the 2022 BIO International Conference in San Diego, this podcast discusses the results of Vital Transformation's latest research study…
Vital Health PodcastDanny Seiden leads Arizona’s push against march-in rights
With the Center for Medicare and Medicaid Services’ recent decision to limit access to Biogen’s Alzheimer’s treatment, and with drug pricing…
Vital Health PodcastFlagship Pioneering’s Tom Dilenge On Accelerated Approvals
One of the brightest minds in DC, Tom Dilenge recently joined Flagship Pioneering, the highly respected bio platforms innovation company behind such…
Vital Health PodcastGeorge Vradenburg, USAgainstAlzheimer's, and CMS' NCD
George Vradenburg is the co-founder and chairman of USAgainstAlzheimer's, a patient advocacy organization founded in 2010, which has successfully worked to…
Vital Health PodcastSue Peschin - “CMS is in an untenable position” on Alzheimer’s disease
When the Centers for Medicare and Medicaid Services (CMS) published its draft determination requiring further clinical trials in Alzheimer’s disease…
Vital Health PodcastVT analyzed CMS' Alzheimer's disease draft guidance - it's REALLY bad
The Centers for Medicare & Medicaid Services (CMS) recently released draft guidance that, in the future, proposes to only reimburse FDA approved treatments for…